Since then, several case reports have shown dupilumab to be an effective treatment for different subtypes of pemphigoid, including adolescent BP, eczema-like BP, IgA BP, anti-PD-1/PD-L1-induced BP, vesicular pemphigoid, and pemphigoid nodularis (19–32). This evidence concerns the gene CD79A and autoimmune bullous skin disease.